1. Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination.
- Author
-
das Neves SP, Delivanoglou N, Ren Y, Cucuzza CS, Makuch M, Almeida F, Sanchez G, Barber MJ, Rego S, Schrader R, Faroqi AH, Thomas JL, McLean PJ, Oliveira TG, Irani SR, Piehl F, and Da Mesquita S
- Subjects
- Animals, Mice, Humans, Vascular Endothelial Growth Factor C metabolism, Mice, Inbred C57BL, Cell Survival, Remyelination, Female, Male, Adaptive Immunity, Oligodendroglia metabolism, Meninges immunology, Brain metabolism, Brain immunology, Myelin Sheath metabolism, Multiple Sclerosis immunology, Multiple Sclerosis metabolism, Lymphatic Vessels
- Abstract
The precise neurophysiological changes prompted by meningeal lymphatic dysfunction remain unclear. Here, we showed that inducing meningeal lymphatic vessel ablation in adult mice led to gene expression changes in glial cells, followed by reductions in mature oligodendrocyte numbers and specific lipid species in the brain. These phenomena were accompanied by altered meningeal adaptive immunity and brain myeloid cell activation. During brain remyelination, meningeal lymphatic dysfunction provoked a state of immunosuppression that contributed to delayed spontaneous oligodendrocyte replenishment and axonal loss. The deficiencies in mature oligodendrocytes and neuroinflammation due to impaired meningeal lymphatic function were solely recapitulated in immunocompetent mice. Patients diagnosed with multiple sclerosis presented reduced vascular endothelial growth factor C in the cerebrospinal fluid, particularly shortly after clinical relapses, possibly indicative of poor meningeal lymphatic function. These data demonstrate that meningeal lymphatics regulate oligodendrocyte function and brain myelination, which might have implications for human demyelinating diseases., Competing Interests: Declaration of interests S.D.M. is listed as an inventor in patents and patent applications concerning modulating lymphatic vessels in neurological diseases (University of Virginia Licensing & Ventures Group and PureTech Ventures LLC). S.R.I. has received honoraria/research support from UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharma, receives licensed royalties on patent application WO/2010/046716 entitled “Neurological Autoimmune Disorders,” and has filed two other patents entitled “Diagnostic method and therapy” (WO2019211633 and US-2021-0071249-A1; PCT application WO202189788A1) and “Biomarkers” (PCT/GB2022/050614 and WO202189788A1)., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF